New, None-live Vaccine against Herpes Zoster ( Shingles)

Mon April 11th 2022

New Vaccine against Herpes Zoster (Shingles).

Anyone who has been infected with varicella-zoster virus, and likely to have had chickenpox previously, is at risk of developing shingles at some stage in their life. Shingles can affect people of any age but is more common as we get older. By the age of 85 years, at least half of us will have had shingles. In addition to getting older, other factors can increase the risk of getting shingles, such as having a weakened immune system, psychological stress, physical trauma, being female and having a genetically close relative who has had shingles.

A non-live Shingles vaccine has not been available in New Zealand until now, leaving PID patients vulnerable.

New to the NZ market this month, Shingrix is a non-live (Adjuvanted recombinant protein subunit vaccine) suited to most immune deficient patients. This vaccine is however only privately funded (not provided free through MOH). Patients over the age of 50 years are eligible.

Talk to your medical team now for clinical information about whether this new vaccine is suitable for you.

https://www.immune.org.nz/sites/default/files/resources/Written%20Resources/DiseaseHerpesZosterImac20220314.pdf